Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Decoding the Raf-Mek-Erk-Rsk Pathway in Prostate Cancer: From Molecular Mechanisms to Clinical Opportunities

May 15, 2026

[British Journal of Cancer] Whilst inhibitors of the RAF-MEK-ERK-RSK pathway have demonstrated clinical utility in other cancers this has not been realized in prostate cancer. The reasons for this include a lack of predictive biomarkers for, and the unique landscape of pathway activation.

HOXD11-NMDAR Signaling Drives Neuroendocrine Prostate Cancer and Enables Potential Therapeutic Intervention As a Target of Memantine

May 15, 2026

[Cell Reports] Using single-cell RNA sequencing of transgenic adenocarcinoma of the mouse prostate mice across pathological stages, scientists found an early neuroendocrine-initiating cluster marked by elevated HOXD11, conserved in human neuroendocrine prostate cancer.

LGALS9 Blockade Augments Vaccine-Induced Immune Responses against Prostate Cancer

May 15, 2026

[Journal for Immunotherapy of Cancer] Scientists generated recombinant adenoviral vaccines encoding PSMA and LGALS9 (Ad-PSMA and Ad-LGALS9) for antigen expression in vitro and in vivo. They evaluated therapeutic efficacy in murine subcutaneous, bone metastatic, and humanized prostate cancer models.

The RPS15-DDX21 Complex Drives Prostate Malignancy through Transcriptional Activation of SCD1

May 15, 2026

[Oncogene] Researchers demonstrated that RPS15 significantly promotes proliferation and migration in prostate cancer through the establishment of ribosomal protein S15 (RPS15) knockdown cells and xenograft models.

The Microbiome across the Prostate Disease Continuum: From Health and BPH to Prostatitis/CPPS and Cancer

May 15, 2026

[Oncogene] By integrating mechanistic, spatial and clinical evidence, the authors propose a stage-aware framework for the gut–urinary–prostatic axis and delineate when microbial and metabolite signalling meaningfully conditions prostate disease biology—and when it does not.

PARG Inhibition in ATM-Deficient Prostate Cancer: From Mechanistic Discovery to Therapeutic Potential

May 15, 2026

[Journal of Translational Medicine] Researchers identified poly (ADP-ribose) glycohydrolase (PARG) inhibition as a previously unrecognized synthetic lethal vulnerability in ATM-deficient prostate cancer.

MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer

May 15, 2026

[Cancer Research] Scientists identified ecotropic viral integration site 1 (EVI1) as an androgen receptor (AR)-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus.

IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer

May 15, 2026

[Molecular Cancer Therapeutics] Investigators identified insulin-like growth factor–binding protein 3 (IGFBP3) as a key driver of enzalutamide resistance in CRPC. They demonstrated that IGFBP3 expression is significantly upregulated in enzalutamide-resistant C4-2B MDVR cells compared with parental C4-2B cells.

Histone Lactylation Modification Promotes Docetaxel Resistance and Tumor Progression through CNN1-Mediated Autophagy and Cell Cycle Arrest in Castration-Resistant Prostate Cancer

May 15, 2026

[Cell Death Discovery] Clinical analysis revealed significantly increased pan-lactylated protein (Pan Kla) expression in CRPC tissues compared to prostate cancer, accompanied by elevated lactate production and lactate dehydrogenase activity. Higher Pan Kla expression was linked to poor prognosis in CRPC.

Fred Hutch Researchers Receive Prostate Cancer Foundation Young Investigator Awards

May 15, 2026

[Fred Hutch Cancer Center] Two researchers at Fred Hutch Cancer Center, Drs. Pallabi Mustafi and Ruben Raychaudhuri, received Young Investigator Awards from the Prostate Cancer Foundation for their work investigating epigenetic features of aggressive prostate cancer that could lead to more personalized care and better results from existing therapies.

First-in-Human Single-Cell and TCR Atlas Reveals Peripheral Immune Remodeling Before and after Irreversible Electroporation in Prostate Cancer

May 15, 2026

[Journal for Immunotherapy of Cancer] Researchers presented a detailed analysis of paired single-cell data collected before and after irreversible electroporation (IRE). They provide a first-in-human atlas of peripheral immune remodeling after IRE in localized prostate cancer.

An Orally Bioavailable Pan-αV/α5β1 Integrin Antagonist Prevents Aggressive Prostate Cancer Progression via Suppressing Both Oncogenic Signals and CD47-Mediated Immune Escape

May 15, 2026

[Molecular Cancer] In preclinical models, C19-9N overcame enzalutamide resistance in CRPC xenografts, suppressed bone metastatic progression, and exhibited superior efficacy to platinum/taxane therapies in neuroendocrine prostate cancer .

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.